Rivaroxaban Market By Indication (Atrial Fibrillation (AF), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Prophylaxis of Venous Thromboembolism (VTE) and Others (Acute Coronary Syndrome, etc.)), By Formulation (Tablets and Suspension), By Patient Type (Adults and Pediatrics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: Jan 2025
- Report ID: 138110
- Number of Pages: 257
- Format:
-
keyboard_arrow_up
-
-
- Bayer AG Company Profile
- Janssen Pharmaceuticals, Inc.
- Interquim SA
- Natco Pharma
- Mylan N.V.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd. Company Profile
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Hetero Labs Limited
- Fresenius Kabi AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals
- Dr. Reddys Laboratories Ltd Company Profile
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Pfizer Inc Company Profile
- Eisai Co., Ltd.
- Amgen Inc.
- Cipla Limited Company Profile
- Other Prominent Players
- settingsSettings
Our Clients
- 138110
- Jan 2025
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
